Total raised
$3.6M
Last: Series A 2018-05
Stage
Series A
Founded
2013
Headcount
3
HQ
Shoham
Sector
Health Tech & Life Sciences
About
Eximore is developing ophthalmic drug-delivery products. The company's initial target is a noninvasive punctal plug designed to release glaucoma drugs, controlled over a long period of time. Eximore's product aims to circumvent the need to apply daily eye drops and thereby improve compliance.
Funding history · 2 rounds · $3.6M total
2018-05
Series A
$3.0M
2013-12
Seed
$600K
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2CB2B
Highlights
1 PatentsVerified
Tags
bioconvergencepersonalizationnon-invasiveeye-diseasesmedical-technologiesdrug-deliveryophthalmologyglaucomamedical-devicesadherenceclinicsbiopharmaceutical